Board of Directors

Samuel Broder, MD

Position: Former Director of the National Cancer Institute

Samuel Broder is the former head of the National Cancer Institute (NCI), the largest and most important Agency for cancer research in the world. President Ronald Reagan appointed Dr. Broder to serve as Director of the NCI in 1989, and he held the position for six years.  While at the NCI, he also oversaw the development of numerous anti-cancer therapeutic agents, such as TAXOL®. As NCI Director, Dr. Broder helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer, and he inaugurated the highly successful SPORE Program.

Dr. Broder joined the Celera Corporation at its founding in 1998, as the Executive Vice President for Medical Affairs and Chief Medical Officer, and helped advance the human genome project, i.e., the elucidation of the 3 billion letters of code that make up human DNA. His most recent operational position was as SVP, Health Sector, Intrexon Corp, with responsibilities for gene therapy and synthetic biology.  He has served on numerous BODs and SABs.

Dr. Broder spent his entire career in translational medicine, and his laboratory interests have included antiretroviral therapy, the relationship between immunodeficiency disorders and cancer, the human genome, and the proteomics of cancer cells. In the mid-1980s, in response to the AIDS pandemic, he focused his attention on HIV-1/AIDS.  His laboratory played a major role in developing the first 3 agents approved by FDA specifically to treat the AIDS virus. These are the novel nucleosides Retrovir® (AZT), Videx® (ddI), and HIVID® (ddC).

Dr. Samuel Broder graduated from the University of Michigan Medical School in Ann Arbor in 1970. He did an internship and residency in Internal Medicine at Stanford University in Palo Alto, and then did subspecialty training in medical oncology at the National Cancer Institute in Bethesda. He is the author or co-author of over 340 scientific publications, and is an inventor on many patents. He has received numerous scientific awards related to his research in cancer and AIDS. He was elected to the National Academy of Medicine of the National Academy of Sciences in 1993.

Samuel Broder, MD

Former Director of the National Cancer Institute

Samuel Broder is the former head of the National Cancer...

Casey Cunningham, MD

Position: Chief Scientific Officer, Santé Ventures

Casey Cunningham, MD is the Chief Scientific Officer of Santé Ventures. Dr. Cunningham received his fellowship training in oncology and hematology at the Harvard Medical School, where he subsequently served on the faculty for a number of years. In 1999, he became the Associate Director of the Mary Crowley Cancer Research Institute in Dallas, Tx. The MCMRI performs early phase clinical trials in oncology and Dr. Cunningham had a particular focus on gene and immune approaches. During his time at MCMRI, Casey also provided consulting services to biotech and pharma companies, advising them on early stage drug development. Dr. Cunningham joined Santé Ventures in 2008 as CSO but has also served in operating roles for several of the fund’s portfolio companies.

Casey Cunningham, MD

Chief Scientific Officer, Santé Ventures

Casey Cunningham, MD is the Chief Scientific Officer of Santé...

James Eadie, MD

Position: Partner, Santé Ventures

James Eadie, MD received his MD from Harvard Medical School, an MBA from the University of Texas McCombs School Of Business, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital.

Previously, James served in the Air Force and was the medical director and Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, a level-one trauma center in San Antonio. He completed two tours in Iraq as a critical care transport team chief and as the emergency department commander. He separated honorably as a Major in 2008.

James Eadie, MD

Partner, Santé Ventures

James Eadie, MD received his MD from Harvard Medical School,...

J. Joseph Kim, PhD

Position: President & CEO, INOVIO Pharmaceuticals

J. Joseph Kim, PhD, entrepreneur, immunologist, and health policy leader, is co-founder and chief executive officer of Inovio, a biotechnology company leading the world in developing novel immunotherapies – medicines that attack a broad array of cancers and challenging infectious diseases by training the body’s immune system to identify and fight disease. He previously developed vaccines for Merck & Co.

An immunologist by training, Joseph holds an MIT undergraduate degree, a PhD in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015, Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders.

He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on Inovio’s breakthroughs and the pharmaceutical landscape. MIT’s Technology Review magazine called him “one of the world’s top innovators.” Joseph is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system.

J. Joseph Kim, PhD

President & CEO, INOVIO Pharmaceuticals

J. Joseph Kim, PhD, entrepreneur, immunologist, and health policy leader,...

Sangwoo Lee

Position: Managing Director — Korea Investment Partners US Inc.

Mr. Lee is Head of Korea Investment Partners (KIP’s) US office based in Silicon Valley and actively explores cross-border investments to contribute to the global expansion of Korea Investment Partners.  He is currently managing over 12 companies in his investment portfolio and participates actively on more than 7  boards. Portfolio companies range from biotech/healthcare companies such as Enlivex, Prokarium, PDC Line, Atrogi and KAHR to IT/Fintech companies such as Pavilion Data Systems and SecuLetter.

Before his career in Venture Capital, Mr. Lee spent 18 years in diverse positions and companies including his 12 years of entrepreneur experience in the IT industry including Samsung Electronics, Dasan networks, Neomtel and Polidigm. In the latter two, he cofounded the companies and led the teams as top management officer. The image compression algorithm for cell phone of Neomtel was de facto standard in Korea at early 2000s and the company went on to IPO at 2007.

Sangwoo Lee

Managing Director — Korea Investment Partners US Inc.

Mr. Lee is Head of Korea Investment Partners (KIP’s) US...

Niranjan Y. Sardesai, PhD

Position: Founder, President & CEO

Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer. He held positions of increasing responsibility after joining the company in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. For Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of Inovio’s pipeline products to secure major licensing deals totaling over $1 Bn with pharma partners.

Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARKTM), bladder cancer and a multi-marker test for ovarian cancer (HE4).

Dr. Sardesai received a PhD in Chemistry from the California Institute of Technology and a MBA from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. Dr. Sardesai has authored over 120 peer-reviewed manuscripts and was recognized by PharmaVoice magazine as one of the top 100 most influential and inspirational leaders across the life sciences industry (2015).

Niranjan Y. Sardesai, PhD

Founder, President & CEO

Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a...